1Thorgeirsson S, et al. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339–46.
2Theise N, et al. Dysplastic nodules and hepatocarcinogenesis. Clin Liv Dis 2002;6:497–512.
3Seki S, et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin Cancer Res 2000;6:3469–73.
4Parkin DM, et-al. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94 (2): 153-6. Int. J. Cancer (link) - Pubmed citation.
5Semelka RC, et al. Focal hepatic lesions: comparison of dual phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001; 13: 39.
6S R Digumarthly at al., MRI in detection of hepatocellular carcinoma (HCC), Cancer Imaging (2005) 5, 20-24 DOI:10.1102/1470-7330.2005.005.
7E. Niendorf at al., Contrast Enhanced MRI in Diagnosis of HCC, Diagnostic 2015, 5, 383-398; doi:10.3390/diagnostics5030383.
8Frydrychowicz, A, et al Hepatobiliary MR imaging with gadolinium-based contrast agents. J. Magn. Reson. Imaging 2012, 35, 492–511.
9E. Niendorf at al., Contrast Enhanced MRI in Diagnosis of HCC, Diagnostic 2015, 5, 383-398; doi:10.3390/diagnostics5030383.
10Wald, C et al. New OPTN/UNOS policy for liver transplant allocation: Standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013, 266, 376–382.
11Bruix, J.; Sherman, M.; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53, 1020–1022.
12LIRADS vs 2018 and OPTN guidelines.
13C. Van der Pol et all, Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review, Gastroenterology 2019;156:976–986.